Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.48 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.47 |
| ▸ | CCNC | P24863 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL851458 | 0.85 | GPR119 (0.55) | GPR119EGLN2CCNCCDK8KCNH2 | |
| SCHEMBL851888 | 0.83 | HRH3 (0.54) | HRH3EGLN2KCNH2 | |
| SCHEMBL31615907 | 0.80 | GPR119 (0.53) | GPR119EGLN2 | |
| SCHEMBL2208835 | 0.79 | MEN1 (0.64) | GPR119EGLN2CCNCCDK8MEN1 | |
| SCHEMBL27380506 | 0.77 | GPR119 (0.48) | HRH3GPR119EGLN2IRAK4 | |
| SCHEMBL2776233 | 0.77 | GPR119 (0.66) | GPR119IRAK4 | |
| SCHEMBL27381531 | 0.76 | HRH1 (0.53) | HRH3GPR119EGLN2 | |
| SCHEMBL3554489 | 0.76 | PANK3 (0.63) | GPR119EGLN2 | |
| SCHEMBL30546362 | 0.76 | PANK3 (0.63) | GPR119EGLN2 | |
| SCHEMBL850901 | 0.75 | GPR119 (0.49) | GPR119EGLN2CCNCCDK8KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140200225-A1 | PROTEASE INHIBITORS | ORION CORPORATION (FI) | 2014-07-17 | — | — | US | disclosed |
| US-8722930-B2 | Protease inhibitors | ORION CORPORATION (FI) | 2014-05-13 | — | — | US | disclosed |
| US-20120136002-A1 | PROTEASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-05-31 | — | — | US | disclosed |
| EP-2432556-A1 | PROTEASE INHIBITORS | Orion Corporation (FI) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010133748-A1 | PROTEASE INHIBITORS | ORION CORPORATION (FI) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200225-A1 | PROTEASE INHIBITORS | SERPINB1, TMPRSS15, PRSS1 | HRH3 2164/4885GPR119 3130/4885EGLN2 813/4885 |
| US-20120136002-A1 | PROTEASE INHIBITORS | SERPINB1, TMPRSS15, PRSS1 | HRH3 2164/4885GPR119 3130/4885EGLN2 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.